Processa Pharmaceuticals (PCSA) - Quarterly EPS earnings growth

Brandmark of Processa Pharma (PCSA)

The current quarterly EPS growth rate presented by GURU.Markets demonstrates the impact of capital-intensive trials on expenses, where the 81.20 mark records this metric for Processa Pharmaceuticals (PCSA). Growth is based on the reprocessing of legacy molecules to accelerate therapy and a strategic partnership with laboratories for NGC-Cap adaptation, which creates scientific synergy and enables the acquisition of valuable oncology patents.

Processa Pharmaceuticals, Inc. (PCSA) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/10/2026

Analytical breakdowns for Processa Pharmaceuticals (PCSA)

- market value and analyst target forecast:
Price Chart processapharmaceuticals.com|PCSA - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Processa Pharma|PCSA - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Processa Pharmaceuticals|PCSA - Total Stockholders' Equity|Market Value to Book Value Ratio processapharmaceuticals.com|PCSA - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Processa Pharmaceuticals|PCSA - Long-Term Liabilities to Equity|Short-Term Debt to Equity processapharmaceuticals.com|PCSA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Processa Pharma|PCSA - Long-Term Debt|Company Short-Term Debts Processa Pharmaceuticals|Quick Ratio processapharmaceuticals.com
- earnings and valuation multiples indicators:
PCSA - Company Net Income|Expected Profit Processa Pharmaceuticals|PCSA - Business Payback Period|Future Price to Earnings processapharmaceuticals.com|PCSA - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Processa Pharma|PCSA - Operating profit EBITDA|Net earnings per share for the last 12 months Processa Pharmaceuticals|PCSA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months processapharmaceuticals.com|PCSA - Earnings per share trend in current year|Earnings growth forecast for next year Processa Pharmaceuticals
Summary company analytics:Processa Pharmaceuticals
Manufactured product of processapharmaceuticals.com

Processa Pharmaceuticals (PCSA) investments in green laboratory upgrades and energy efficiency directly impact operating expenses, which is reflected in the net income per share dynamics. By analyzing the growth rate of quarterly earnings per share, an investor assesses the real speed of capital recovery, avoiding a premature entry into the asset before a sustainable upward yield trend forms.

Analysis of competing companies

Olema (OLMA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months PBYI|GLSI (Greenwich LifeSciences, Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Zentalis Pharma (ZNTL)|Quarterly EPS earnings growth MGNX|PSTV - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Eagle Pharmaceuticals, Inc. EGRX